secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-06-01T12:45:27+00:00
Accession:  0001213900-26-063177
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs
--------------------------------------------------------------------------

- 92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.
- EASI-90 rates: 44.4% at Week 4 and 51.9% at Week 8 for GX-03 vs 30.4% and 34.8% vehicle.
- No treatment-related serious adverse events, tolerability issues, or discontinuations reported.
- Enrollment nearing completion; company optimizing trial endpoints and planning FDA meeting.
- Detailed data to be presented at Jefferies Global Healthcare conference on June 4, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/0001213900-26-063177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/ea0292880-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-063177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer